Hop rho iso-alpha acids, berberine, vitamin D3 and vitamin K1 favorably impact biomarkers of bone turnover in postmenopausal women in a 14-week trial
- 385 Downloads
Osteoporosis is a major health issue facing postmenopausal women. Increased production of pro-inflammatory cytokines resulting from declining estrogen leads to increased bone resorption. Nutrition can have a positive impact on osteoporosis prevention and amelioration. The objective of this study was to investigate the impact of targeted phytochemicals and nutrients essential for bone health on bone turnover markers in healthy postmenopausal women. In this 14-week, single-blinded, 2-arm placebo-controlled pilot study, all women were instructed to consume a modified Mediterranean-style low-glycemic-load diet and to engage in limited aerobic exercise; 17 randomized to the placebo and 16 to the treatment arm (receiving 200 mg hop rho iso-alpha acids, 100 mg berberine sulfate trihydrate, 500 IU vitamin D3 and 500 μg vitamin K1, twice daily). Thirty-two women completed the study. Baseline nutrient intake did not differ between arms. At 14 weeks, the treatment arm exhibited an estimated 31% mean reduction (P = 0.02) in serum osteocalcin (a marker of bone turnover), whereas the placebo arm exhibited a 19% increase (P = 0.03) compared to baseline. Serum 25-hydroxyvitamin D (25(OH)D) increased by 13% (P = 0.24) in the treatment arm and decreased by 25% (P < 0.01) in the placebo arm. The between-arm differences for OC and 25(OH)D were statistically significant. Serum IGF-I was increased in both arms, but the increase was more significant in the treatment arm at 14 weeks (P < 0.01). Treatment with hop rho iso-alpha acids, berberine sulfate trihydrate, vitamin D3 and vitamin K1 produced a more favorable bone biomarker profile that supports a healthy bone metabolism.
KeywordsBone turnover OC Kinase modulation Humulus lupulus Postmenopausal women
We thank Lincoln Bouillon for trial supervision, and Michelle Babb, Barbara Schiltz, Mabel Lorenzi-Albe, Cynthia Baxter, Leslie Pilkington, Scott Stockmyer, Julie Triggs, and Lara Wax for technical and clinical assistance. The study was funded by Metagenics Inc.
- 5.Wells G, Cranney A, Peterson J, Boucher M, Shea B, Robinson V, Coyle D, Tugwell P (2008) Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev CD004523Google Scholar
- 6.Wells GA, Cranney A, Peterson J, Boucher M, Shea B, Robinson V, Coyle D, Tugwell P (2008) Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev CD001155Google Scholar
- 7.Wells GA, Cranney A, Peterson J, Boucher M, Shea B, Robinson V, Coyle D, Tugwell P (2008) Etidronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev CD003376Google Scholar
- 8.Lamb JJ (2006) Osteoporosis. In: Kohlstadt I (ed) scientific evidence for musculoskeletal, bariatric, and sports nutrition. CRC Press, Boca Raton, pp 473–490Google Scholar
- 20.Tripp M, Konda VR, Hall A, Desai A, Carroll B, Darland G, Lerman R, Emma D, Bland JS (2006) Rho iso-alpha acids, a modified hop (Humulus lupulus) extract, inhibits protein kinases involved in autoimmune disease. FASEB J. 20:A1125Google Scholar
- 26.Lerman RH, Minich DM, Darland G, Lamb JJ, Schiltz B, Babish JG, Bland JS, Tripp ML (2008) Enhancement of a modified Mediterranean-style, low glycemic load diet with specific phytochemicals improves cardiometabolic risk factors in subjects with metabolic syndrome and hypercholesterolemia in a randomized trial. Nutr Metab (Lond) 5:29CrossRefGoogle Scholar
- 42.Melmed S, Jameson JL (2008) Disorders of the anterior pituitary and hypothalamus. In Fauci AS et al (eds) Harrison’s principles of internal medicine, chap. 333, McGraw-Hill Professional, New YorkGoogle Scholar